Celeventus AB

We have a new method to dry vaccines and other biologically sensitive substances with preserved activity. Our mission is to help more humans get essential vaccines through improved manufacturing technology

Target group

Researchers, postdocs and PhD students are all relevant. Scope adjusted based on applicant.

About the company

Celeventus AB helps develop thermostable vaccines using a new scalable & gentle process to dry sensitive biologically active substances in room temperature.

The project

We are seeking an intern to join our Phase 2 collaboration with Professor Jan Holmgren's team at Gothenburg University, developing thermostable diagnostic reagents using Celeventus' innovative gentle drying technology. Building on successful cholera vaccine work, this project focuses on creating dry formulations of enzyme-conjugated antibodies (IgG-HRP and IgG-AP) used in ELISA diagnostics.

Current diagnostic reagents require cold-chain storage, limiting access in low-resource settings. Our technology could enable room-temperature stable diagnostic reagents while preserving full enzymatic activity, dramatically improving global diagnostic accessibility.

The intern will operate our patented drying system, conduct comparative stability testing between liquid and dried formulations, and perform ELISA-based analysis. Work includes method development, data analysis, and contributing to publications and conference presentations.

Expected Outcomes: Experience in biotechnology innovation and bioanalytical methods while contributing to technology that could revolutionize global health diagnostics. Deliverables include optimized protocols, stability data, and potential publication co-authorship.

Location: Laboratory facilities in Stockholm, Sweden

Time Period: Q4 2025 to Q1 2026, flexible arrangements possible

The candidate

Relevant backgrounds:

• Microbiologists with experience in vaccine development and testing, particularly with cholera vaccines.
• Biochemists specializing in protein stability and formulation, as preserving the biological activity of the vaccine is crucial.
• Pharmaceutical scientists with expertise in drug delivery systems, especially those focused on oral or pulmonary delivery, as the dry powder vaccine may have novel administration routes.
• Chemical engineers with knowledge of spray drying and particle engineering, to optimize the drying process and particle size distribution.

Contact information

Name: Johan Acevedo

Email: johan@celeventus.com

Telephone: +46 (0) 73 697 5200
Company website: www.celeventus.com